Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uvadex with ECP for high-risk acute GVHD
NCT04291261Phase 2Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- May 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of methoxsalen in Acute Graft-Versus-Host Disease (aGVHD), sponsored by University Medical Center Hamburg-Eppendorf. Started May 2020; status: active, not recruiting.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT04291261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291261.